WASHINGTON, DC, March 13, 2017 – UsAgainstAlzheimer’s Co-Founder and Chairman George Vradenburg has released the following statement, calling for swift Congressional action to confirm Dr. Scott Gottlieb as the next FDA Commissioner.
“Dr. Gottlieb brings a solid history of agency experience,” Vradenburg said. “We have every confidence that he is dedicated to moving safe and effective therapies swiftly through the FDA review process and into the hands of patients and clinicians. This experience and perspective will be critical as we anticipate the arrival of much-needed therapies to treat Alzheimer’s over the next few years. We anticipate and trust his commitment to advancing the agency’s understanding of what matters most to people with or at risk for this disease and their caregivers. We will face uncharted territory as we assess the risk individuals will be willing to bear in exchange for the potential promise of stemming the progression of Alzheimer's, and we look forward to our partnership with him and the FDA to navigate this course.”
Dr. Gottlieb was Deputy Commissioner at the FDA during the George W. Bush administration (2005-2007), and he is currently a partner at New Enterprise Associates and a fellow at the American Enterprise Institute.
UsAgainstAlzheimer’s continues to call for the Administration and Congress to seek solutions designed to reduce the time and cost it takes to develop Alzheimer’s therapies. The development of innovative Alzheimer’s medicines already exceeds a dozen years and more than $1.5 billion on average.
###
UsAgainstAlzheimer's is an innovative, patient-centered non-profit demanding – and delivering – a solution to Alzheimer’s. Driven by the suffering of millions of families, UsAgainstAlzheimer’s presses for greater urgency from government, industry and the scientific community in the quest for an Alzheimer's cure – accomplishing this through its own patient-centered effective leadership, collaborative advocacy and strategic investments.
Founded in 2010, UsAgainstAlzheimer’s has worked across sectors to: (1) secure the national goal of preventing and effectively treating Alzheimer’s by 2025; (2) help secure nearly $1 billion in additional public funding for Alzheimer’s research over the past few years; (3) drive global efforts that resulted in the leaders of the world’s most powerful nations, the G7 group, to embrace a similar 2025 goal and to call for greater levels of research investment and collaboration; (4) transform the system of Alzheimer’s clinical trials for greater speed, efficiency and quality; and (5) forge a global process of industry, regulators and payers to bring greater clarity to the approval and payment of innovative medicines for Alzheimer’s.
Contact: Tim Tassa
Phone: 202-263-2580
Email: [email protected]